Skip to content
Roboearth – Lifestyle
Author:
Zepto Life Technology
NIAID Awards Zepto Life Technology Contract Valued at Up to $8.9 Million to Advance the First Deployable Liquid Biopsy Platform for Infectious Disease
August 11, 2026
Zepto Life Technology Introduces FungiFlex® Pneumocystis jirovecii and FungiFlex® Mold Plus
July 15, 2026
Zepto Life Technology Receives FDA Breakthrough Device Designation for Targeted Liquid Biopsy Test for Invasive Mold Infections
June 3, 2026